Pfizer looks to sustain older products in Japan through new business unit
This article was originally published in Scrip
Executive Summary
Pfizer's Japanese subsidiary has begun commercial operations at a new established products division, through which it will more actively promote and develop its portfolio of older drugs and launch selected generics against a background of major patent expiries.